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Long-Term Follow-Up
of Severe Dysplasia and
Carcinoma In Situ of
the Bronchus
To the Editor:
In a previous issue of the journal,
Banerjee1 brilliantly reviewed the
available data from the literature about
the natural history of bronchial prein-
vasive lesions. We congratulate the
author for this very important and dif-
ficult work.
In his review, the author cited our
work published in the American Journal
of Respiratory and Critical Care Medicine
in 20012 that described the 24 months
follow-up of 416 preinvasive lesions in
104 patients. Indeed, we agree with the
author’s conclusions that limited individ-
ual lesion follow-up in most studies, as
well as interferences with local or even
systemic treatments, complicate the as-
sessment of the potential aggressiveness
of lesions known to be characterized by a
long carcinogenesis process.
In a recent published work, not
cited in Banerjee’s review, we provided
some answers to these limitations3 in
studying the long-term evolution of 37
patients and 54 high-grade preinvasive
lesions—31 carcinoma in situ (CIS) and
23 severe dysplasia (SD)—during a 12-
year period. Our study was performed
using auto-fluorescence bronchoscopy
with repeated bronchial biopsy sam-
pling over time, with a mean of seven
biopsies per individual lesion during
the follow-up and molecular analysis
of the baseline lesions. We believe that
this very long monitoring authorizes to
draw reliable conclusions on the ag-
gressiveness of high-grade lesions, de-
spite the fact that conservative endo-
bronchial treatment was applied to
persisting or relapsing lesions.
To reliably identify the factors that
are linked to the lesions’ evolution over
time, we used a very restrictive definition
of “progression,” including local progres-
sion to invasive cancer. We also defined a
locally treated lesion as “treatment resis-
tant” that recurred at any time during the
monitoring period and “treatment sensi-
tive” those that did not reoccur after local
treatment, whereas regressing lesions
were those that spontaneously disappeared
without treatment. This allowed us to clas-
sify accurately the more aggressive lesions
in the progression or treatment resistant
groups, while ascertaining that the spon-
taneously regressing lesions were truly be-
nign ones (Table 1).
In this study, we observed that all
the lesions that progressed to invasive
cancer were initially classified as CIS (7
of 7) according to World Health Orga-
nization 1999 standards,4 and 10 of 31
CIS were resistant to several courses of
endoscopic treatments, whereas 10 of 31
CIS were treatment sensitive and only 4
of 31 CIS spontaneously regressed with-
out recurrence during follow-up. Our
study also provided valuable informa-
tion on long-term SD and CIS patients
outcome, with, at the study end point,
nine deaths attributable to lung cancer
including four deaths directly related to
the progression of the initial high-grade
bronchial lesion. In addition, using care-
ful laser microdissection and robust mo-
lecular analysis on the baseline le-
sions,3,5 we could demonstrate that
losses of heterozygosity (LOH) of chro-
mosome 3p and 9p are significantly
more frequent in CIS compared with
SD, whereas 3p LOH seems to be a
strong predictor of progression in the
whole group of lesions and in the CIS
group (Table 1).
Altogether, our results lend strong
support to the World Health Organization
classification for the premalignant bron-
chial lesions, which clearly differentiates
CIS from SD,4 not only in confirming
their different outcomes, as we had previ-
ously observed,2 but also in providing ev-
idence of significant differences at the mo-
lecular level.
Finally, our contribution shows
that CIS histology as defined by 1999
WHO classification and the molecular
analysis of 3p LOH are useful indicators
of the evolution of high-grade preinva-
sive bronchial lesions. The molecular
analysis could easily be integrated in the
management decision tree of CIS and
SD of the bronchial epithelium.
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TABLE 1. Outcome of Bronchial Severe Dysplasia and Carcinoma In Situ
According to the Molecular Analysis of the Lesion at Baseline
Progression to
Invasive Cancer Tt R Tt S Regression P
Lesions with at
least one LOH
7/7 10/11 13/17 9/19 0.01a
3p LOH 6/6 7/11 6/16 2/17 0.0001b
5q LOH 3/5 3/10 1/15 5/17 0.09b
9p LOH 5/7 6/9 10/15 5/15 0.20b
a 2 test.
b Fisher’s exact test.
Tt R, treatment resistant; Tt S, treatment sensitive; LOH, loss of heterozygosity.
Modified from Am J Respir Crit Care Med. 2008;177:880–886.
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